Navigation Links
Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Date:5/8/2008

facturing

scale-up of the Company's rHuPH20 enzyme.

-- Selling, general and administrative expenses for the first quarter of

2008 were $4.2 million, compared with $2.0 million for the first

quarter of 2007, reflecting increases in compensation expenses

including share-based compensation expenses, as well as legal and

facilities expenses as compared with the prior-year quarter.

-- Cash and cash equivalents were $92.6 million as of March 31, 2008,

compared with $97.7 million as of December 31, 2007. During the

quarter the Company received a $3.5 million product-based payment for

HYLENEX.

Conference Call

Halozyme management will host a pipeline update conference call tomorrow to discuss these topics beginning at 8:00 a.m. PT (11:00 a.m. ET). To participate via telephone, please call 888-256-9044 for domestic callers, or 706-643-5585 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reservation number is 44830661. The conference call will be broadcast live over the Internet at http://www.halozyme.com and the replay will be available on the Company's website for 30 days.

About HYLENEX

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in the formulation. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX recombinant if sensitizati
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
2. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
3. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics Amends Stockholder Rights Plan
7. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
8. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
9. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
10. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
11. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... COLUMBIA, Md. (PRWEB) September 17, 2014 ... Nexera-e Comprehensive Two-Dimensional Liquid Chromatograph (2D-LC), which ... most complex sample matrices. The system provides ... of sample analytes, which is beneficial to ... food extracts, and natural products. , Comprehensive ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2
... 5, 2011 TetraLogic Pharmaceuticals , a biopharmaceutical ... treat cancer, today announced the initiation of a Phase ... candidate, TL32711, in elderly patients with acute myelogenous leukemia ... Hospital of the University of Pennsylvania and is an ...
... FRANCISCO, Calif., Dec. 5, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected ... cardiovascular disease, today said that it plans to present ... Metabolic Disorders Conference on Tuesday, December 6, 2010 at ...
... Corp. announced today that Wayne R. Gombotz, Ph.D. has ... Officer.  Dr. Gombotz brings a significant amount of ... at Immune Design.  He will oversee product development ... candidates. (Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO ...
Cached Biology Technology:TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 2TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 3Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
(Date:9/16/2014)... Fire began on September 13, 2014. The fire is ... currently over 2,300 acres in size and is mostly ... Fire was calm Monday night due to higher humidity. ... point and beginning to construct a fireline on the West ... are working on the fire: , 7 20-person Crews, 4 ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2
... UT Southwestern Medical Center researchers have identified compounds ... disease, a finding that may eventually lead to a ... degenerative nerve disorders. "Our studies have uncovered a ... for other neurodegenerative diseases," said Dr. Ilya Bezprozvanny, professor ...
... A new study conducted by a team of ... light on a possible new approach to treat the ... enzyme that connects extracellular fibers. The study, published online ... the direction of Katya Ravid, PhD, professor of medicine ...
... MARC (Minority Access to Research Careers) Program has announced the ... of Reproduction (SSR) Annual Meeting in Portland, Oregon from July ... to promote the entry of underrepresented minority students, postdoctorates and ... to encourage the participation of young scientists at the 2011 ...
Cached Biology News:Compound may provide drug therapy approach for Huntington's disease 2BUSM study identifies new potential approaches to treat myelofibrosis 2
... This complete kit contains enough ... from a total of 5 ... and includes the StemSep red ... reagents and buffers for the ...
... LNA technology enables sensitive, fast and specific ... chromosomes. Short hybridisation time ( ... and chromosome spreads Multiplex capability ... Probes available with different ...
... enzyme glycerol 3-phosphate dehydrogenase catalyzes a ... and glycerol 3-phosphate, with NAD as ... during differentiation of progenitor cells into ... this enzyme has been used as ...
...
Biology Products: